ospemifene
Selected indexed studies
- Ospemifene for Genitourinary Syndrome of Menopause: Patient Selection. (Int J Womens Health, 2024) [PMID:38855356]
- The 2022 hormone therapy position statement of The North American Menopause Society. (Menopause, 2022) [PMID:35797481]
- Ospemifene efficacy and safety data in women with vulvovaginal atrophy. (Gynecol Endocrinol, 2020) [PMID:32329400]
_Worker-drafted node — pending editorial review._
Connections
ospemifene is a side effect of
Sources
- Management of Menopausal Symptoms: A Review. (2023) pubmed
- Ospemifene for Genitourinary Syndrome of Menopause: Patient Selection. (2024) pubmed
- The 2022 hormone therapy position statement of The North American Menopause Society. (2022) pubmed
- Ospemifene efficacy and safety data in women with vulvovaginal atrophy. (2020) pubmed
- Effects of ospemifene on bone in postmenopausal women. (2019) pubmed
- Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause. (2019) pubmed
- Ospemifene in the treatment of vulvovaginal atrophy. (2014) pubmed
- Ospemifene for vulvar and vaginal atrophy: an overview. (2020) pubmed
- Ospemifene and vulvovaginal atrophy: an update of the clinical profile for post-menopausal women. (2024) pubmed
- ▼Ospemifene for vulvar and vaginal atrophy. (2019) pubmed